26, March 2020
The rising global geriatric population, increasing volumes of surgeries, sports-related & trauma injuries, growing need for more effective blood-loss management, and increasing clearances of bio-surgery products by various regulatory authorities is estimated to contribute healthy growth rate in the global biosurgery market in the coming decade.
The major vendors who are currently holding a major share are:
In 2017, Baxter dominated the global biosurgery market. The company has a strong presence across North America, Europe, the Middle East, Africa, and the Asia Pacific. Some of the major end-users of the company include hospitals, nursing homes, kidney dialysis centers, clinical and medical research laboratories, rehabilitation centers, doctors’ offices, and patients at home under physician supervision. The company’s strong manufacturing and distribution network across the globe has enabled it to establish a strong foothold in the biosurgery market. Collaborations and product launches are some of the major strategies adopted by the company to grow in this market.
Johnson & Johnson (J&J) company offers its products through two of its subsidiaries, namely, Ethicon, Inc. (US) and DePuy Synthes (US). The major end-users of the company’s products include physicians, nurses, clinics, and hospitals. Over the years, the company has strongly established in North America, Europe, the Middle East and Africa, and the Asia Pacific. The company has a wide product portfolio, which enables it to strengthen its presence in the biosurgery market. Like J&J, Ethicon has a diverse product portfolio, and more than 600 general surgical products of the company are listed in the US FDA. Most of these products have patent exclusivity in the US beyond 2020, which will help the company sustain its market position. Ethicon harnesses J&J’s worldwide infrastructure to sell its products. Ethicon also gets benefited through synergies with its parent company in R&D, technological know-how, business strategies, and project implementation experience.
Medtronic (Ireland) is a multinational medical technology company that manufactures and markets products for alleviating pain and restoring health. The company’s products are used by hospitals, clinics, third-party healthcare providers, distributors, and other institutions (including governmental healthcare programs and group purchasing organizations). Medtronic has a well-diversified business and strong geographic presence in the market. The company has a strong presence in the US market and is expanding its reach in emerging markets. For instance, in 2016, the company opened its regional headquarters in Singapore to improve its presence in the Asia Pacific region. Medtronic offers soft-tissue attachment products through its subsidiary Covidien. Covidien offers synthetic monofilament meshes, composite meshes, and biologic meshes. The company also offers tack applicators for mesh fixation. Medtronic offers its mesh fixation tacks under the brand name-ProTack.
B. Braun Melsungen AG, together with its subsidiaries, manufactures, markets, and sells various healthcare products and services in the areas like anesthesia, intensive care, cardiology, extracorporeal blood treatment, and surgery worldwide. The company’s hospital care division offers infusion, nutrition, and pain therapy products, including infusion and nutrition solutions, and medications; products for preparing medications, patient access, administration process, and discharge management products; and infusion equipment and supplies, infusion and injection solutions, intravenous catheters, clinical nutrition products, and pumps and their associated systems for inpatient and outpatient care. The Aesculap division offers products for the general surgery, orthopedic joint replacement and regenerative therapy, neurosurgery, laparoscopy, interventional vascular diagnostics and treatment, degenerative spine surgery, and cardiothoracic surgery, as well as consulting, optimization, and repair services. The company’s Out Patient Market division provides various services in the areas of infection prevention, diabetes, incontinence and urology, stoma, and wound management for physicians in private practice, outpatient and inpatient care services, and pharmacies. Its B. Braun Avitum division offers products in the areas of hemodialysis, acute dialysis, and apheresis for the chronic and acute kidney failure. This division has a network of 350 dialysis centers in Europe, Asia, Latin America, and South Africa. The company was founded in 1839 and is headquartered in Melsungen, Germany. B. Braun Melsungen AG is a subsidiary of B. Braun Holding GmbH & Co. KG.
C. R. Bard, Inc. designs, manufactures, packages, distributes and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and invasive devices for treating peripheral vascular and end-stage renal diseases. It also provides urology products, which include Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for treating prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia. In addition, the company offers oncology products, such as specialty vascular access catheters and ports, vascular access ultrasound devices, dialysis access catheters, and enteral feeding devices to treat and manage various cancers, and other diseases and disorders.
The company also provides surgical specialty products comprising implanted grafts and fixation devices for hernia and soft tissue repairs; and hemostats and surgical sealants, as well as irrigation, wound drainage, and original equipment manufacturers’ products. The company sells its products directly to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities through hospital/surgical supply and other medical specialty distributors. C. R. Bard, Inc. was founded in 1907 and is headquartered in Murray Hill, New Jersey. As of December 29, 2017, C. R. Bard, Inc. operates as a subsidiary of Becton, Dickinson and Company.
Prevalent cases of terrorist attacks in today’s world is increasing the need for severe standards of security for public safety, and the global market for biometric technology scrupulously accommoda..
Prevalent cases of terrorist attacks in today’s world is increasing the need for..